Who are Tavilermide ophthalmic solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vedolizumab IV, Natalizumab (Tysabri), BG00002 (natalizumab), Vedolizumab SC, natalizumab (NTZ).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tavilermide-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tavilermide ophthalmic solution — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tavilermide ophthalmic solution (Tavilermide ophthalmic solution) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrin antagonist. Area: Ophthalmology.

phase 3 Integrin antagonist Integrins (α4β1, αLβ2, and other integrin subtypes) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Tavilermide ophthalmic solution (Tavilermide ophthalmic solution) — Mimetogen Pharmaceuticals USA, Inc.. Tavilermide is a small-molecule integrin antagonist that inhibits cell adhesion and migration by blocking integrin-mediated interactions, reducing inflammatory cell infiltration in ocular tissues.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tavilermide ophthalmic solution TARGET	Tavilermide ophthalmic solution	Mimetogen Pharmaceuticals USA, Inc.	phase 3	Integrin antagonist	Integrins (α4β1, αLβ2, and other integrin subtypes)
Vedolizumab IV	Vedolizumab IV	Takeda	marketed	Integrin antagonist monoclonal antibody	α4β7 integrin
Natalizumab (Tysabri)	Natalizumab (Tysabri)	Cornerstone Health Care, PA	marketed	Monoclonal antibody; integrin antagonist	α4β1 integrin (VLA-4)
BG00002 (natalizumab)	BG00002 (natalizumab)	Biogen	marketed	Monoclonal antibody (integrin antagonist)	α4β1 integrin
Vedolizumab SC	Vedolizumab SC	Takeda	marketed	Integrin antagonist; monoclonal antibody	α4β7 integrin
natalizumab (NTZ)	natalizumab (NTZ)	University Hospital, Clermont-Ferrand	marketed	Monoclonal antibody (integrin antagonist)	α4β1 integrin (VLA-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrin antagonist class)

Mimetogen Pharmaceuticals USA, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tavilermide ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/tavilermide-ophthalmic-solution. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing